Literature DB >> 31875981

Staging and clinical correlations of lymphoscintigraphy for unilateral gynecological cancer-related lymphedema.

Marco Pappalardo1,2, Chieh Lin3, Olivia A Ho1, Chang-Fu Kuo4, Chia-Yu Lin1, Ming-Huei Cheng1.   

Abstract

BACKGROUND: This study was to investigate the lymphoscintigraphy findings for the diagnosis and severity in unilateral gynecological cancer-related lymphedema (GCRL) and to correlate lymphoscintigraphy stages with the clinical findings.
METHODS: Patients with unilateral GCRL who underwent lymphoscintigraphy were staged using the presence of ileo-inguinal lymph nodes, distal-lymphatic ducts, and dermal backflow findings. Taiwan Lymphoscintigraphy Staging (TLS) was divided into three patterns and seven stages: normal drainage (L-0); partial obstruction (P-1, P-2, and P-3); and total obstruction (T4, T-5, and T-6). Correlations between clinical lymphedema severity and TLS were evaluated using analysis of variance and multivariable linear regression analyses.
RESULTS: A total of 141 patients with unilateral GCRL were divided as follows: 6 (4.3%) in normal drainage, 56 (39.7%) in partial-obstruction, and 79 (56%) in total obstruction. Cellulitis episodes, circumferential difference, and computed tomography (CT) volumetric difference were shown to be statistically different between TLS stages (P < .001 for all). Total obstruction stages were the most significant factors associated with the severity of circumferential difference (β = 19.72, 25.54, 32.42, respectively; P < .05) and CT volumetric difference (β = 36.04, 45.12, 52.78, respectively; P < .01).
CONCLUSIONS: Total lymphatic obstruction was present in 56% of unilateral GCGL. Lymphoscintigraphy stages were statistically correlated with episodes of cellulitis, circumferential difference and CT volumetric difference in unilateral GCRL.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  gynecologic cancer-related lymphedema; lower limb lymphedema; lymphedema grading system; lymphedema microsurgery; lymphoscintigraphy staging system

Mesh:

Year:  2019        PMID: 31875981     DOI: 10.1002/jso.25817

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Three-dimensional analysis of dermal backflow in cancer-related lymphedema using photoacoustic lymphangiography.

Authors:  Anna Oh; Hiroki Kajita; Nobuaki Imanishi; Hisashi Sakuma; Yoshifumi Takatsume; Keisuke Okabe; Sadakazu Aiso; Kazuo Kishi
Journal:  Arch Plast Surg       Date:  2022-01-15

2.  Pathological Changes in the Lymphatic System of Patients with Secondary Lower Limb Lymphedema Based on Single Photon-Emission Computed Tomography/Computed Tomography/Lymphoscintigraphy Images.

Authors:  Takahiro Fujiyoshi; Taro Mikami; Koukichi Hashimoto; Saori Asano; Eiko Adachi; Shintaro Kagimoto; Yuichiro Yabuki; Shinya Kitayama; Shinobu Matsubara; Jiro Maegawa; Toshinori Iwai; Atsushi Ishibe; Etsuko Miyagi; Tomohiro Kaneta
Journal:  Lymphat Res Biol       Date:  2021-08-19       Impact factor: 2.589

3.  Liposuction and Controlled Compression Therapy Reduce the Erysipelas Incidence in Primary and Secondary Lymphedema.

Authors:  Tobias Karlsson; Mattias Hoffner; Håkan Brorson
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-05-06

4.  Visual analysis of global research output of lymphedema based on bibliometrics.

Authors:  Yun-Dong Zhang; Xue Zhang; Xin-Yu Wang; Dong-Mei Han; Jian-Shi Du
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

5.  Correlation between Lymphatic Surgery Outcome and Lymphatic Image-Staging or Clinical Severity in Patients with Lymphedema.

Authors:  Hirofumi Imai; Shuhei Yoshida; Toshiro Mese; Solji Roh; Asuka Fujita; Ayano Sasaki; Shogo Nagamatsu; Isao Koshima
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

Review 6.  Breast Cancer-Related Lymphedema: Recent Updates on Diagnosis, Severity and Available Treatments.

Authors:  Marco Pappalardo; Marta Starnoni; Gianluca Franceschini; Alessio Baccarani; Giorgio De Santis
Journal:  J Pers Med       Date:  2021-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.